FDA Approved: REVUFORJ — Original Application (Syndax Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves REVUFORJ (revumenib) from Syndax for patients with acute leukemias that harbor KMT2A gene rearrangements, in relapsed or refractory settings.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia with Kmt2a Rearrangements
• Acute Myeloid Leukemia with Kmt2a Rearrangements
• Leukemia with Kmt2a Rearrangements

Drugs mentioned

• REVUFORJ (REVUMENIB)

Snippet

ORIG AP for REVUFORJ (REVUMENIB)